Профиль Diaxonhit SA Act Porteur-Nominatif provient regroupement
Diaxonhit engages in the research and commercialization of diagnostic products. Its portfolio consists of proprietary diagnostic products in the following areas: transplantation, infectious diseases and cancer diagnosis. The company markets Tetanus Quick Stick used for the evaluation of patient's immune status against tetanus, and BJI Inoplex for the diagnosis of bone joint prosthetic infections. Diaxonhit was founded on October 15, 1997 and is headquartered in Paris, France.